

Review

Not peer-reviewed version

Microbiota Modulation: Examining the Effects on Pathogen Colonization and Infection

[Abhinandan Patil](#) * and Neha Singh

Posted Date: 17 July 2023

doi: [10.20944/preprints2023071093.v1](https://doi.org/10.20944/preprints2023071093.v1)

Keywords: Bacteria; microbiota; pathogens; dysbiosis; infections



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Microbiota Modulation: Examining the Effects on Pathogen Colonization and Infection

Abhinandan Patil ¹ and Neha Singh ²

¹ D. Y. Patil Education Society, (Deemed to be University), Kolhapur

² Department of Microbiology, Pt. JNM Medical Raipur

* Correspondence: author- abhisirdyp@gmail.com

Abstract: The trillions of bacteria that live in and on our bodies make up the human microbiota, which is a very important part of keeping us healthy and protecting us from pathogenic infections. Dysbiosis is when there are changes in the composition and variety of the microbiota. This can upset the delicate balance between the host and its microbes, making the host more vulnerable to pathogens. Understanding the complicated link between microbiota and pathogens is important for coming up with effective ways to change microbiota and boost the body's defenses against infections. This study looks at how microbiota modulation affects the spread of pathogens and infections. It talks about how the makeup of microbiota affects how susceptible you are to pathogens. It shows how a healthy microbiota can protect you by making it hard for pathogens to grow and take over. The review also goes into detail about how the microbiota protects against pathogens, such as through competitive exclusion, the production of antimicrobial compounds, and the regulation of immune reactions. The study also looks at the idea of dysbiosis and how it is linked to pathogenic shifts. Disruptions in the microbiota can make it easier for pathogens to grow and make it harder for the host to fight off infections. It focuses on the need to recover microbial balance to improve the host's defenses and lower risks caused by pathogens. There is also talk about the use of probiotics, prebiotics, and fecal microbiota transplantation (FMT) as ways to change the microbiome. The goal of these interventions is to restore the diversity and function of microbes, improve the integrity of barriers, and boost the immune system's reaction to pathogens. The review shows how these methods could be used to change the microbiota and make it easier for the body to fight off infections. In conclusion, knowing how the microbiota and pathogens work together in a complicated way can help a lot when it comes to making specific interventions for microbiota modulation. Strategies that restore the balance of microbes and boost the host's defenses could stop pathogens from taking over and making people sick. More study needs to be done in this area to improve therapeutic approaches and use the microbiota to its fullest extent to fight infectious diseases.

Keywords: Bacteria; microbiota; pathogens; dysbiosis; infections

Makeup of the Microbiota and Susceptibility to Pathogens

The microbiota is the group of microorganisms that live in and on the human body. These microorganisms are important for health and homeostasis. The make-up and variation of the microbiota can have big effects on how the host and pathogens interact, including how likely it is that a pathogen will colonize or infect the host. Understanding the complex link between microbiota composition and pathogen susceptibility is essential for figuring out how infectious diseases work and coming up with new ways to treat them as follows [1-6]:

Pathogen Susceptibility and the Makeup of the Microbiota

Pathogen sensitivity can be affected by the types of microbiota in many ways. First of all, a healthy and diverse microbiota can make it harder for pathogens to take over by filling ecological niches and fighting for resources with pathogens. Some friendly bacteria make substances that kill other bacteria or create a microenvironment that makes it hard for pathogens to grow. Also, the microbiota can change the immune responses of the host, making it harder to spot and fight off

pathogens. This sensitive balance can be upset by a change in the makeup of the microbiota, which is called dysbiosis. Dysbiosis is caused by a decrease in beneficial commensal bacteria.

Effects of Changes in Microbiota on Immune Function

The microbiome is a very important part of how the immune system develops and works. For example, commensal bacteria in the gut connect with the gut-associated lymphoid tissue and help immune cells grow up. Changes in the microbiome can mess up this cross-talk, which can cause immune dysregulation and make it harder for the body to fight off pathogens. Changes in specific bacterial taxa and a decrease in the number of different kinds of microbes have been linked to an increased risk of getting illnesses in the respiratory, urinary, and gastrointestinal systems.

Possible Mechanisms Behind Interactions Between Microbiota and Pathogens

Changes in the makeup of microbiota may make pathogens more or less dangerous in a number of ways. There are changes in the production of antimicrobial peptides, the development of pattern recognition receptors that help recognize pathogens, and the way immune cells work and how cytokines send signals. Also, the microbiota can change the physical and chemical qualities of the mucosal surfaces, which can affect how pathogens stick to and get inside the body.

Effects on Therapeutic Interventions

Understanding how the makeup of bacteria affects a pathogen's ability to spread opens up ways to treat diseases. Strategies that change the microbiota, such as probiotics, prebiotics, and fecal microbiota transplantation, have shown promise in recovering microbial balance and improving the host's defenses against pathogens. Targeted methods that help helpful commensal bacteria grow or stop pathogenic microbes from growing could be used to avoid and treat infectious diseases. The make-up and variety of the microbiome are very important in determining how susceptible a host is to colonization and infection by pathogens. Changes in the microbiota can throw off the delicate balance between friendly and harmful microorganisms, which can hurt tolerance to colonization and immune function. In the future, it may be possible to prevent and treat infectious diseases by figuring out how microbiota and pathogens interact and creating targeted therapeutic strategies to restore microbial homeostasis [7,10–21].

Mechanisms of Protection by Microbiota:

The trillions of bacteria that live in and on our bodies make up the human microbiota, which is very important for keeping us healthy and protecting us from pathogens. A healthy microbiota can protect against pathogen colonization and illness in many ways. It can act as a barrier and stop pathogens from taking hold. Understanding these processes is important for figuring out how the microbiota and pathogens interact with each other and using their therapeutic potential [7–11].

The Role of Competition And Exclusion among Microbes

One of the main ways that a good microbiota protects against pathogens is by making it harder for pathogens to live there. Beneficial bacteria that live together with pathogens can outcompete pathogens for limited resources and places to live, which stops pathogens from establishing and growing. This competition can happen in different ways, such as through nutrient competition, the production of antimicrobial compounds, and niche exclusion, in which commensals fill and protect specific ecological niches, leaving no room for pathogens.

Antimicrobial Substances are Made by

The microbiota can make a wide range of antimicrobial chemicals that can directly stop pathogens from growing and living. Antimicrobial peptides, bacteriocins, and secondary metabolites with antimicrobial qualities are some of these substances. These antimicrobial chemicals can target

and interfere with the way pathogens do things, like make cell walls or keep their membranes from leaking. This can stop or kill the pathogen.

Controlling the Immune Responses of the Host

The microbiome is a big part of how the immune system of the host is made, and this is a key way to keep pathogens from taking over and getting sick. Beneficial “commensal” bacteria can help immune cells grow and mature, leading to a balanced and strong immune reaction. This can make it easier for the immune system to find and get rid of pathogens, stop inflammation from getting out of hand, and help tissues heal. Also, the microbiota can affect the production of cytokines and chemokines, which control the recruitment and stimulation of immune cells and help fight off pathogens in other ways.

Improvement of the Way the Epithelial Barrier Works

The microbiome helps the epithelial barrier, which is the first line of defense against pathogens, stay strong and in good shape. Beneficial bacteria help keep the epithelial layer healthy and working in many ways, such as by regulating tight junctions, making mucus, and changing how immune cells interact with the epithelium. A strong epithelial barrier keeps pathogens out and limits their ability to get to the cells below.

Systemic Immune Tolerance is Caused by

In addition to local effects, the microbiome can also cause immune tolerance throughout the body. This helps stop the immune system from overreacting and causing inflammation. Commensal microorganisms can help the immune system make regulatory immune cells and hormones that fight inflammation. This immune tolerance can limit the damage caused by immune responses when they meet pathogens. This stops tissue harm and makes it easier to get rid of pathogens. A healthy microbiota has a big effect on how pathogens colonize and cause infections by using a wide range of defenses. These include microbial competition and exclusion, making antimicrobial substances, adjusting the immune reactions of the host, improving the function of the epithelial barrier, and inducing systemic immune tolerance. To understand how the microbiota and pathogens work together, it is important to figure out how these processes work. By learning more about this topic, we might be able to come up with new ways to promote and keep a healthy microbiota and use it to protect against infectious diseases [12–15].

Dysbiosis and Changes in Pathogens

The human microbiome is a complicated group of microorganisms that live in different parts of the body. A microbiota that is well-balanced and full of different kinds of bacteria is very important for staying healthy and preventing illnesses. But dysbiosis, which is a change in the makeup and diversity of the microbiota, can cause pathogenic shifts that make it easier for harmful pathogens to grow and take over. Understanding the processes behind pathogenic shifts caused by dysbiosis is important for finding ways to bring back a healthy microbiota and reduce the risk of infection [16–21].

Changes in the Structure of Microbial Communities

When there is dysbiosis, there is often a change in the number and types of microbial groups in the microbiota. This can cause a drop in the number of helpful commensal bacteria, which usually help keep pathogenic bacteria in check. At the same time, dysbiosis can promote the growth of possibly pathogenic microorganisms or the loss of protective microorganisms, making it easier for pathogens to colonize and grow.

Changes in the Way Microorganisms Work

Changes in bacteria metabolism often go along with dysbiosis. These changes can lead to pathogenic shifts. Changes in the production of metabolites, such as short-chain fatty acids (SCFAs), antimicrobial peptides, or secondary metabolites, may be seen in dysbiotic bacteria. These metabolites can affect how pathogens grow and live or change the immune reactions of the host. Changes in microbial metabolism caused by dysbiosis can upset the delicate balance between microbiota and pathogens, making it easier for dangerous microorganisms to grow.

Impaired Immune Function

The microbiome is a very important part of how the immune system learns and changes. Changes in the microbiota that are caused by dysbiosis can hurt immune function, making it harder to spot and respond to pathogens. Dysbiotic microbiota can lead to less production of antimicrobial peptides, less activation of immune cells, or out-of-whack cytokine responses. This makes it easier for pathogens to colonize and attack the body.

Disrupted Barrier Function

The microbiome helps keep the gut, lungs, and skin healthy and working. Dysbiosis can hurt the operation of the barrier, which weakens the body's physical and immune defenses against pathogens. Changes in mucus production, epithelial barrier integrity, or tight junction proteins can make it easier for pathogens to move, invade, and hurt tissue. Barrier function is changed by dysbiosis, which makes it easier for pathogens to get past the body's defenses and cause illnesses.

Changes in How Microorganisms Interact

The relationships between different types of microbes make up the microbiota, which is a complex network. Dysbiosis can mess up these interactions, which can lead to a loss of microbial variety and functional redundancy, which are important for a healthy microbiota. When microbial relationships are messed up, niches can be made that help pathogenic microorganisms grow and stay around. Also, dysbiosis can lead to the loss of helpful cross-feeding relationships. This is when one microbe makes compounds that help other protective microbes grow, which is another factor in pathogenic shifts. Pathogenic shifts caused by dysbiosis show how complicated the link is between the microbiota and the risk of infection. Changes in microbiota makeup, changes in microbial metabolism, changes in immune function, changes in barrier function, and changes in how microbes interact with each other all make it easier for pathogens to colonize and infect the body. Understanding the causes of dysbiosis and pathogenic changes is important for making treatments that return a healthy microbiota and reduce the risk of infection. Future study that tries to figure out how these mechanisms work could lead to specific ways to prevent and treat infections by changing the composition of microbiota and promoting a healthy microbial community [21–30].

Therapeutic Ways to Change the Microbiota

The microbiota of a person is very important for keeping them healthy and protecting them from germs. Dysbiosis, which is caused by an imbalance or change in the makeup of microbiota, has been linked to a higher risk of getting sick. Therapeutic approaches that change the microbiota could help restore microbial homeostasis and boost the host's defenses against pathogens. This study looks at the use of probiotics, prebiotics, and fecal microbiota transplantation (FMT) as possible ways to change the microbiota and boost the immune response of the host to fight off pathogenic infections [21–32].

Probiotics

Probiotics are live bacteria that help the health of the host when given in the right amounts. Pathogens can be killed directly by these good bacteria because they compete for nutrients and

binding sites, make antimicrobial compounds, and change the immune reaction of the host. Probiotics can also bring back microbial variety and improve barrier function, which makes it less likely that pathogens will take up residence and cause an infection. Clinical studies have shown that certain strains of probiotics are effective at preventing and treating a number of infectious illnesses, such as stomach and lung infections [32–37].

Prebiotics

Prebiotics are chemicals that can't be digested, but they help good bacteria in the gut grow and do their jobs. By helping good microbes grow, prebiotics can indirectly change the makeup and function of the microbiota, making it easier for the host to fight off pathogens. It has been shown that prebiotics increase the production of short-chain fatty acids, improve the integrity of the intestinal barrier, and make the immune reaction stronger. These effects change the microbiome and make it harder for pathogens to live in the body and cause infections.

FMT Stands for Fecal Microbiota Transplantation

FMT is when feces from a healthy source are given to a person who has a dysbiotic microbiota. This method is meant to bring back a diverse and well-balanced microbial population in the recipient, which will protect them from pathogens that could cause infection or colonization. Most research on FMT has been done on how to treat recurring *Clostridioides difficile* infections, where it has been very successful. The transferred microbiota can bring back the range of microorganisms, improve the function of the barrier, and change how the immune system responds. All of these things help the body be more resistant to pathogenic infections. Researchers are still looking into how FMT could be used to treat other infectious diseases and conditions linked to dysbiosis.

Therapies that Work Together

Combining different types of therapy, like probiotics, prebiotics, and FMT, may have synergistic benefits on the microbiota and the defense against pathogens. Using certain strains of probiotics along with prebiotics can help good bacteria colonize and stay in the body, while FMT can bring a diverse and healthy microbial community. These combination therapies may be able to fully restore microbial homeostasis, strengthen the host's defenses, and lower the chance of infections caused by pathogens. Strategies for changing the microbiota, such as using probiotics, prebiotics, and FMT, offer hopeful ways to treat diseases by making the microbiota healthy and balanced again. These treatments can directly stop pathogens from growing, make barriers work better, and change how the immune system responds. Combination therapies could make microbiota modulation even more successful and offer a complete way to avoid and treat infectious diseases linked to dysbiosis. More study in this area will help to create targeted and individualized interventions that use the power of the microbiota to make the host more resistant to pathogens [25–32,37].

Conclusion

The microbiome is a big part of what makes up our immune system and keeps us safe from diseases. Dysbiosis, which is caused by an imbalance in the microbial community, can make people more vulnerable to pathogens and upset the delicate balance between the host and the microbiome. But therapeutic approaches for microbiota modulation offer potential ways to restore microbial homeostasis and boost the host's defenses against pathogens. Probiotics have been shown to be effective in avoiding and treating a number of infectious diseases because they can directly kill microbes and change how the immune system responds. By adding good bacteria, probiotics can make pathogens compete for resources, make antimicrobial chemicals, and help the body's immune system fight off infections. On the other hand, prebiotics feed the good bacteria that live in the gut. By encouraging the growth of only good bacteria, prebiotics can indirectly change the makeup and function of the microbiota, making it easier for the host to fight off pathogens. By making short-chain fatty acids, these good bacteria improve the integrity of the intestinal barrier and boost the immune

response. Fecal microbiota transplantation (FMT) has become a powerful way to bring back a varied and well-balanced group of microorganisms. FMT has been very successful in treating recurrent *Clostridioides difficile* infections, where it can successfully restore a healthy microbiota and protect against pathogen colonization and infection. Researchers are still looking into how FMT could be used to treat other infectious diseases and conditions linked to dysbiosis. Combining different kinds of therapy, like probiotics, prebiotics, and FMT, shows a lot of promise for microbiota modulation and pathogen protection on a broad scale. Combination therapies may offer a more complete and successful way to prevent and treat infectious diseases by improving microbial diversity, barrier function, and immune responses at the same time. Overall, we are learning more about the complicated relationship between bacteria and pathogens, which is leading to the creation of new ways to treat microbiota modulation. These methods could improve the host's defenses, reduce pathogen colonization and infection, and pave the way for personalized interventions that use the power of the microbiota to improve health and fight pathogens. It is important to keep doing study in this area if we want to learn more about how microbiota protect us and how to make the best therapeutic interventions for microbiota modulation.

References

1. Afzal M, Mazhar SF, Sana S, Naeem M, Rasool MH, Saqalein M, et al. Neurological and cognitive significance of probiotics: a holy grail deciding individual personality. *Future Microbiol.* 2020;15:1059–1074. doi: 10.2217/fmb-2019-0143.
2. Markowiak P, Slizewska K. Effects of probiotics, prebiotics, and synbiotics on human health. *Nutrients.* 2017 doi: 10.3390/nu9091021.
3. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. *Microbiome.* 2020;8(1):36. doi: 10.1186/s40168-020-00821-0.
4. Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut microbiome: profound implications for diet and disease. *Nutrients.* 2019 doi: 10.3390/nu11071613.
5. Panebianco C, Andriulli A, Pazienza V. Pharmacomicobiomics: exploiting the drug-microbiota interactions in anticancer therapies. *Microbiome.* 2018;6(1):92. doi: 10.1186/s40168-018-0483-7.
6. Khan AA, Shrivastava A, Khurshid M. Normal to cancer microbiome transformation and its implication in cancer diagnosis. *Biochem Biophys Acta.* 2012;1826(2):331–337. doi: 10.1016/j.bbcan.2012.05.005.
7. Khan AA, Nema V, Khan Z. Current status of probiotics for prevention and management of gastrointestinal cancers. *Expert Opin Biol Therapy.* 2020 doi: 10.1080/14712598.2021.1828858.
8. Khan AA, Khurshid M, Khan S, Alshamsan A. Gut microbiota and probiotics: current status and their role in cancer therapeutics. *Drug Dev Res.* 2013;74(6):365–375. doi: 10.1002/ddr.21087.
9. Sedighi M, Zahedi Bialvaei A, Hamblin MR, Ohadi E, Asadi A, Halajzadeh M, et al. Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities. *Cancer Med.* 2019;8(6):3167–3181. doi: 10.1002/cam4.2148.
10. Zur HH. The search for infectious causes of human cancers: where and why. *Virology.* 2009;392(1):1–10. doi: 10.1016/j.virol.2009.06.001.
11. Ishaq S, Nunn L. *Helicobacter pylori* and gastric cancer: a state of the art review. *Gastroenterol Hepatol Bed Bench.* 2015;8(Suppl 1):S6–S14.
12. Khan AA, Abuderman AA, Ashraf MT, Khan Z. Protein-protein interactions of HPV-Chlamydia trachomatis-human and their potential in cervical cancer. *Future Microbiol.* 2020;15:509–520. doi: 10.2217/fmb-2019-0242.
13. Khan AA, Khan Z, Malik A, Kalam MA, Cash P, Ashraf MT, et al. Colorectal cancer-inflammatory bowel disease nexus and felony of *Escherichia coli*. *Life Sci.* 2017;180:60–67. doi: 10.1016/j.lfs.2017.05.016.
14. Khan AA, Khan Z, Malik A, Shrivastava A, Jain SK, Alshamsan A. Computational prediction of *Escherichia coli* proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. *Cancer Lett.* 2015;364(1):25–32. doi: 10.1016/j.canlet.2015.04.024.
15. Khan AA. In silico prediction of *Escherichia coli* proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology. *J Comput Biol J Comput Mol Cell Biol.* 2014;21(6):466–475. doi: 10.1089/cmb.2014.0001.
16. Khan AA, Cash PE. *E. coli* and colon cancer: is mutY a culprit? *Cancer Lett.* 2013;341(2):127–131. doi: 10.1016/j.canlet.2013.08.003.
17. Tewari M, Mishra RR, Shukla HS. *Salmonella typhi* and gallbladder cancer: report from an endemic region. *Hepat Pancreat Dis Int HBPD INT.* 2010;9(5):524–530.
18. Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. *Curr Oncol Rep.* 2014;16(10):406. doi: 10.1007/s11912-014-0406-0.

19. Jenkins SV, Robeson MS 2nd, Griffin RJ, Quick CM, Siegel ER, Cannon MJ, et al. Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking. *Cancer Res.* 2019;79(23):5999–6009. doi: 10.1158/0008-5472.CAN-18-4108.
20. Gao Z, Guo B, Gao R, Zhu Q, Qin H. Microbiota dysbiosis is associated with colorectal cancer. *Front Microbiol.* 2015;6:20. doi: 10.3389/fmich.2015.00020.
21. Xuan C, Shamoonki JM, Chung A, Dinema ML, Chung M, Sieling PA, et al. Microbial dysbiosis is associated with human breast cancer. *PLoS ONE.* 2014;9(1):e83744. doi: 10.1371/journal.pone.0083744.
22. Malla MA, Dubey A, Kumar A, Patil A, Ahmad S, Kothari R, Yadav S. (2021). Optimization and elucidation of organophosphorus and pyrethroid degradation pathways by a novel bacterial consortium C3 using RSM and GC-MS-based metabolomics. *Journal of the Taiwan Institute of Chemical Engineers.* 144:104744.
23. Munot N, Kandekar U, Rikame C, Patil A, Sengupta P, Urooj S, Bilal A. (2022). Improved Mucoadhesion, Permeation and In Vitro Anticancer Potential of Synthesized Thiolated Acacia and Karaya Gum Combination: A Systematic Study. *Molecules.* 27(20):6829.
24. Munot N, Kandekar U, Giram PS, Khot K, Patil A, Cavalu S. (2022). A Comparative Study of Quercetin-Loaded Nanocochleates and Liposomes: Formulation, Characterization, Assessment of Degradation and In Vitro Anticancer Potential. *Pharmaceutics.* 14(8):1601.
25. Manikyam HK, Tripathi P, Patil SB, Lamichhane J, Chaitanya M, et al. (2020). Extraction, purification, and quantification of hesperidin from the immature Citrus grandis/maxima fruit Nepal cultivar. *Asian Journal of Natural Product Biochemistry.* 20(1).
26. Patil A, Munot N, Patwekar M, Patwekar F, Ahmad I, Alraey Y, Alghamdi S, et al. (2022). Encapsulation of lactic acid bacteria by lyophilisation with its effects on viability and adhesion properties. *Evidence-based Complementary and Alternative Medicine.* 2022.
27. Nalawade AS, Gurav RV, Patil AR, Patwekar M, Patwekar F. (2022). A comprehensive review on morphological, genetic and phytochemical diversity, breeding and bioprospecting studies of genus *Chlorophytum* Ker Gawl. from India. *Trends in Phytochemical Research.* 6(1):19–45.
28. Patil KG, Balkundhi S, Joshi H, Ghewade G. (2011). MEHSANA BUFFALO MILK AS PREBIOTICS FOR GROWTH OF LACTOBACILLUS. *International Journal of Pharmacy and Pharmaceutical Research.* 1(1):114-117.
29. Das N, Ray N, Patil AR, Saini SS, Waghmode B, Ghosh C, Patil SB, et al. (2022). Inhibitory effect of selected Indian honey on colon cancer cell growth by inducing apoptosis and targeting the β -catenin/Wnt pathway. *Food & Function.* 13(15):8283-8303.
30. Patil MJ, Mali V. (2021). The Diverse Cytotoxicity Evaluation of Lactobacillus Discovered from Sheep Milk. *Acta Scientific Pharmaceutical Sciences.* 5(12):69-70.
31. Abhinandan P SP, John D. (2020). Probiotic potential of *Lactobacillus plantarum* with the cell adhesion properties. *Journal of Global Pharma Technology.* 10(12):1-6.
32. Patil A, Pawar S, Disouza J. (2018). Granules of unistain lactobacillus as nutraceutical antioxidant agent. *INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH.* 9(4):1594-1599.
33. Patil A, Mali V, Patil R. (2019). Banana fibers camouflaging as a gut worm in a 6-month-old infant. *Iberoamerican Journal of Medicine.* 2(3):245-247.
34. Munot NM, Shinde YD, Shah P, Patil A, Patil SB, Bhinge SD, Formulation and Evaluation of Chitosan-PLGA Biocomposite Scaffolds Incorporated with Quercetin Liposomes Made by QbD Approach for Improved Healing of Oral Lesions. *AAPS PharmSciTech.* 24 (6), 147.
35. Patil, A. Psychology in the Age of Technology Dependence and the Mobile Dilemma. *Preprints.org* 2023, 2023070101. <https://doi.org/10.20944/preprints202307.0101.v1>
36. Patil, A.; Kotekar, D.; Chavan, G. Knowing the Mechanisms: How Probiotics Affect the Development and Progression of Cancer. *Preprints.org* 2023, 2023070243. <https://doi.org/10.20944/preprints202307.0243.v1>
37. Vijaykumar Pawar, Abhinandan Patil, Firoj Tamboli, Dinanath Gaikwad, Dipak Mali, Anilkumar Shinde. Harnessing the Power of AI in Pharmacokinetics and Pharmacodynamics: A Comprehensive Review. *14* (2), 426-439.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.